Clinical Trial Update: Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Clinical Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating front-line pemetrexed plus gemcitabine for locally advanced or metastatic non-small cell lung cancer. The study status is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED